These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 37122737)

  • 1. Should treatment of hypogammaglobulinemia with immunoglobulin replacement therapy (IgRT) become standard of care in patients with chronic lymphocytic leukemia?
    Noto A; Cassin R; Mattiello V; Bortolotti M; Reda G; Barcellini W
    Front Immunol; 2023; 14():1062376. PubMed ID: 37122737
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Retrospective Study on the Efficacy of Subcutaneous Immunoglobulin as Compared to Intravenous Formulation in Patients with Chronic Lymphocytic Leukemia and Secondary Antibody Deficiency.
    Visentin A; Molinari MC; Pravato S; Cellini A; Angotzi F; Cavaretta CA; Ruocco V; Imbergamo S; Piazza F; Proietti G; Mauro FR; Trentin L
    Curr Oncol; 2022 Dec; 30(1):274-283. PubMed ID: 36661671
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A systematic review of the cost and cost-effectiveness of immunoglobulin treatment in patients with hematological malignancies.
    Carrillo de Albornoz S; Chai KL; Higgins AM; Petrie D; Wood EM; McQuilten ZK
    Int J Technol Assess Health Care; 2024 May; 40(1):e32. PubMed ID: 38751245
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Canadian perspective on the use of immunoglobulin therapy to reduce infectious complications in chronic lymphocytic leukemia.
    Lachance S; Christofides AL; Lee JK; Sehn LH; Ritchie BC; Shustik C; Stewart DA; Toze CL; Haddad E; Vinh DC
    Curr Oncol; 2016 Feb; 23(1):42-51. PubMed ID: 26966403
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Subcutaneous immunoglobulins in chronic lymphocytic leukemia with secondary antibody deficiency. A monocentric experience during Covid-19 pandemics.
    Innocenti I; Tomasso A; Benintende G; Autore F; Fresa A; Vuono F; Stirparo L; Galli E; D'Arena G; Sorà F; Efremov D; Laurenti L
    Hematol Oncol; 2022 Aug; 40(3):469-474. PubMed ID: 35076123
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunoglobulin replacement therapy in chronic lymphocytic leukaemia patients with hypogammaglobulinaemia and infection.
    Keegan A; Dennington PM; Dhondy N; Mulligan SP
    Eur J Haematol; 2022 Jun; 108(6):460-468. PubMed ID: 35152500
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Natural History of Untreated Primary Hypogammaglobulinemia in Adults: Implications for the Diagnosis and Treatment of Common Variable Immunodeficiency Disorders (CVID).
    Ameratunga R; Ahn Y; Steele R; Woon ST
    Front Immunol; 2019; 10():1541. PubMed ID: 31379811
    [No Abstract]   [Full Text] [Related]  

  • 8. Current clinical practice and challenges in the management of secondary immunodeficiency in hematological malignancies.
    Na IK; Buckland M; Agostini C; Edgar JDM; Friman V; Michallet M; Sánchez-Ramón S; Scheibenbogen C; Quinti I
    Eur J Haematol; 2019 Jun; 102(6):447-456. PubMed ID: 30801785
    [TBL] [Abstract][Full Text] [Related]  

  • 9. IgG testing, immunoglobulin replacement therapy, and infection outcomes in patients with CLL or NHL: real-world evidence.
    Soumerai JD; Yousif Z; Gift T; Desai R; Huynh L; Ye M; Banatwala A; Clear L; Pinaire M; Belsky G; Hsieh YG; Herrick C; Darnell EP; Duh MS; Sanchirico M; Murphy SN
    Blood Adv; 2024 Aug; 8(16):4239-4249. PubMed ID: 38904477
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Controversies about immunoglobulin replacement therapy in HSCT recipients with hypogammaglobulinemia.
    Ohmoto A; Fuji S; Shultes KC; Savani BN; Einsele H
    Bone Marrow Transplant; 2022 Jun; 57(6):874-880. PubMed ID: 35440805
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Subcutaneous Immunoglobulin Therapy for Hypogammaglobulinemia Secondary to Malignancy or Related Drug Therapy.
    Windegger TM; Lambooy CA; Hollis L; Morwood K; Weston H; Fung YL
    Transfus Med Rev; 2017 Jan; 31(1):45-50. PubMed ID: 27450021
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intravenous versus subcutaneous immunoglobulin replacement in secondary hypogammaglobulinemia.
    Spadaro G; Pecoraro A; De Renzo A; Della Pepa R; Genovese A
    Clin Immunol; 2016 May; 166-167():103-4. PubMed ID: 27063866
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Economic evaluation: immunoglobulin vs prophylactic antibiotics in hypogammaglobulinemia and hematological malignancies.
    Carrillo de Albornoz S; Higgins AM; Petrie D; Irving A; Fanning L; Weinkove R; Crispin P; Dendle C; Gilbertson M; Johnston A; Keegan A; Pepperell D; Pullon H; Reynolds J; van Tonder T; Trotman J; Waters N; Wellard C; Weston H; Morrissey CO; Wood EM; McQuilten ZK
    Blood Adv; 2024 May; 8(9):2259-2267. PubMed ID: 38484199
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunomodulatory effects of different intravenous immunoglobulin preparations in chronic lymphocytic leukemia.
    Colado A; Elías EE; Sarapura Martínez VJ; Cordini G; Morande P; Bezares F; Giordano M; Gamberale R; Borge M
    Sci Rep; 2021 Jun; 11(1):12926. PubMed ID: 34155276
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A clinician survey for management of the secondary immunodeficiency caused by hematological malignancies in China.
    Ye C; Liu J; Song X; Zheng S; Liu J
    Medicine (Baltimore); 2021 Jan; 100(3):e23935. PubMed ID: 33545966
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Subcutaneous immunoglobulin in lymphoproliferative disorders and rituximab-related secondary hypogammaglobulinemia: a single-center experience in 61 patients.
    Compagno N; Cinetto F; Semenzato G; Agostini C
    Haematologica; 2014 Jun; 99(6):1101-6. PubMed ID: 24682509
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Intravenous and subcutaneous immunoglobulin therapy].
    Thon V
    Epidemiol Mikrobiol Imunol; 2013 Jul; 62(2):64-73. PubMed ID: 23964967
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early intravenous immunoglobulin replacement in hypogammaglobulinemic heart transplant recipients: results of a clinical trial.
    Sarmiento E; Diez P; Arraya M; Jaramillo M; Calahorra L; Fernandez-Yañez J; Palomo J; Sousa I; Hortal J; Barrio J; Alonso R; Muñoz P; Navarro J; Vicario J; Fernandez-Cruz E; Carbone J
    Transpl Infect Dis; 2016 Dec; 18(6):832-843. PubMed ID: 27639067
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunoglobulin substitution in patients with secondary antibody deficiency in chronic lymphocytic leukemia and multiple myeloma: a representative analysis of guideline adherence and infections.
    Link H; Kerkmann M; Holtmann L; ;
    Support Care Cancer; 2022 Jun; 30(6):5187-5200. PubMed ID: 35257229
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical outcomes of immunoglobulin treatment for patients with secondary antibody deficiency: Data from the Ontario immunoglobulin treatment case registry.
    Abadeh A; Shehadeh S; Betschel S; Waserman S; Cameron DW; Cowan J
    PLoS One; 2023; 18(11):e0294408. PubMed ID: 37971974
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.